Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer
Authors:
- 15 March 2003
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (6) , 1022-1028
Abstract
Purpose: The independent clinical relevance of invasion factors urokinase-type plasminogen activator (uPA)/PAI-1 and HER2 status was evaluated in lymph node-negative breast cancer patients (N = 118) without adjuvant systemic therapy after long-term follow-up of more than 10 years (median, 126 months). Patients and Methods: Levels of uPA and its inhibitor PAI-1 were prospectively measured by enzyme-linked immunosorbent assay in primary tumor tissue extracts. HER2 gene amplification (HER2_AMP) was evaluated by fluorescence in situ hybridization (FISH; Ventana Medical Systems HER-2/neu probe; Tucson, AZ), and HER2 protein overexpression (HER2_EXP) was evaluated by immunohistochemistry (IHC; Oncogene Science antibody Ab-3; Cambridge, MA) on parallel-cut formalin-fixed paraffin-embedded tissue sections. Results: uPA/PAI-1 was high (either one or both factors were high) in 44% of the tumors. HER2_AMP was detected by FISH in 33% of the patients, and HER2_EXP was found by IHC in 44% of the patients. In a multivariate analysis of established and tumor-biologic prognostic factors, uPA/PAI-1 was the only independent prognostic factor for disease-free survival ([DFS]; P < .001; relative risk [RR], 8.3; 95% confidence interval [CI], 3.4 to 20.4). Although HER2_AMP and HER2_EXP did not reach significance for DFS, they were significant for overall survival (OS), even in multivariate analysis (HER2_AMP: P = .004; RR, 3.7; 95% CI, 1.5 to 9.2; HER2_EXP: P = .009; RR, 3.4; 95% CI, 1.4 to 8.7). Conclusion: After long-term follow-up, uPA/PAI-1 levels in primary tumor tissue reliably and strongly indicate an aggressive course of disease in lymph node-negative breast cancer independent of HER2 status. The particular prognostic effect of HER2 status on OS may reflect its ability to predict resistance to systemic therapy.Keywords
This publication has 23 references indexed in Scilit:
- Clinical Utility of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor—1 Determination in Primary Breast Cancer Tissue for Individualized Therapy ConceptsClinical Breast Cancer, 2002
- Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- The urokinase plasminogen activator system as a novel target for tumour therapyFibrinolysis and Proteolysis, 2000
- Do we need prognostic factors in nodal-negative breast cancer?European Journal of Cancer, 2000
- Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapseBreast Cancer Research and Treatment, 1999
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyStem Cells, 1998
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI: Journal of the National Cancer Institute, 1996
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast CancerNew England Journal of Medicine, 1992